UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant ☐

Filed by a Party other than the Registrant ☒

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Under Rule 14a-12

NEXTGEN HEALTHCARE, INC.

(Name of Registrant as Specified in Its Charter)

SHELDON RAZIN

LANCE E. ROSENZWEIG

KENNETH H. FEARN, JR.

RUBY SHARMA

(Name of Persons(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.

☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

☐ Fee paid previously with preliminary materials:

☐          Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

(1) Amount previously paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

Sheldon Razin (“Mr. Razin”), together with the other participants in his solicitation, has filed a definitive proxy statement and accompanying BLUE proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes for the election of his slate of highly-qualified director nominees at the 2021 annual meeting of shareholders (the “2021 Annual Meeting”) of NextGen Healthcare, Inc., a California corporation (the “Company”).

Item 1: On September 24, 2021, Mr. Razin issued the following press release:

The Razin Group Issues Presentation Detailing the Need to Reset the Balance of Power in NextGen Healthcare’s Dysfunctional and Insular Boardroom

Highlights the Company’s Anti-Shareholder Governance, Failed Acquisitions Strategy, Poor Operating Results and Persistent Share Price Underperformance During the Six-Year Chairmanship of Jeffrey Margolis

Outlines the Onerous Terms of the Company’s Proposed Delaware Reincorporation, Which Would Strengthen the Margolis Board’s Power and Weaken Shareholders’ Rights

Opposes the Reelection of Mr. Margolis and Three Entrenched Directors, Who Have Each Held Committee Chair Roles During a Lengthy Period of Stagnation and Underperformance

Urges Shareholders to Vote on the BLUE Proxy Card to Elect the Razin Group’s Minority Slate, Which Possesses a Vision for Improving Governance and Prioritizing Value Creation

IRVINE, Calif.--(BUSINESS WIRE)--Sheldon Razin, who collectively with Lance Rosenzweig and the other participants in his solicitation (collectively, the “Razin Group”) owns approximately 15.2% of the outstanding common shares of NextGen Healthcare, Inc. (NASDAQ: NXGN) (“NextGen Healthcare” or the “Company”), today issued a 70-page presentation that details the case for resetting the balance of power on NextGen Healthcare's nine-member Board of Directors (the "Board"). The Razin Group urges shareholders to vote on the BLUE Proxy Card to elect its four-member slate, which includes Kenneth H. Fearn, Messrs. Razin and Rosenzweig and Ruby Sharma. Please visit www.FixNextGen.com to download the Razin Group slate’s presentation and obtain important information about our value-enhancing vision.

Messrs. Razin and Rosenzweig commented:

"This election contest is about resetting the balance of power in NextGen Healthcare's dysfunctional and insular boardroom in order to ensure that shareholders' best interests are prioritized following six years of anemic revenue growth, deteriorating earnings, dismal capital allocation, poor governance and sustained share price underperformance. We contend that the Company has taken a massive step backward during the past six years under the reign of Chairman Jeffrey Margolis and his fellow Board leaders, Craig Barbarosh, George Bristol and Morris Panner. Their consistent disregard for the Company’s shareholders was mostly recently evidenced by the decision to propose an onerous Delaware reincorporation that would strengthen the Margolis Board’s power while taking away shareholders’ rights, such as the right to fill director vacancies and the right to act by written consent. We believe our minority slate possesses the constructive mindset and relevant skills needed to work with the remaining incumbents to fix the Company's troubling governance, non-accretive capital allocation policy and failed execution against growth objectives. In our view, the Company’s shareholders have a unique opportunity this year to establish a new culture of accountability, incentivization and innovation as a new CEO joins – to be clear, NextGen Healthcare’s new leadership should not be continuously beholden to Mr. Margolis and his allies."

Contacts

Harkins Kovler

Jordan Kovler / Rahsaan Wareham, 212-468-5380

jkovler@harkinskovler.com / rwareham@harkinskovler.com

MKA

Greg Marose / Bela Kirpalani, 646-386-0091

gmarose@mkacomms.com / bkirpalani@mkacomms.com

Item 2: Also on September 24, 2021, Mr. Razin uploaded the following materials to FixNextGen.com: